Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Lexeo Therapeutics (Nasdaq:LXEO) will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 2:35 p.m. ET in New York.
The event will be webcast live with a replay available on Lexeo’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – LXEO
In the May 19 session, LXEO declined 4.88%, reflecting a moderate negative market reaction. Argus tracked a peak move of +11.1% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 2026 earnings | Positive | +5.0% | Q1 2026 results with positive LX2006/LX2020 data and strong cash runway. |
| Apr 27 | Scientific meeting data | Positive | +3.3% | Multiple ASGCT presentations highlighting cardiac gene therapy and manufacturing advances. |
| Mar 30 | FY 2025 earnings | Positive | +8.9% | FY 2025 update with FDA comparability approval, positive interim data and $246.6M cash. |
| Mar 03 | Investor conference | Neutral | -0.8% | Announcement of participation in Leerink Global Healthcare Conference fireside chat. |
| Feb 05 | Investor conferences | Neutral | -5.2% | February 2026 Guggenheim and Oppenheimer investor conference fireside chats. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamental and pipeline updates with positive tone have generally seen aligned positive price reactions, while neutral conference participation headlines have shown mixed to negative follow-through.
Over the past several months, Lexeo reported multiple positive updates. Q4 2025 and Q1 2026 results highlighted strengthening LX2006 and LX2020 data, FDA protocol submissions, and cash balances of $246.6M and $227.6M supporting operations into 2028, with shares reacting +8.92% and +4.97%. Scientific presence was reinforced via ASGCT presentations (+3.29%). In contrast, prior investor-conference announcements on Feb 5 and Mar 3 coincided with modest declines, framing today’s RBC conference news within a pattern of more muted or negative reactions to similar non-data events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
